Mumbai, Oct. 13 -- The facility, launched in September, is a key part of the company's strategy to expand capacity and improve supply chain efficiencies in the North American market.

The site recently underwent a good manufacturing practice (GMP) inspection by the US Food and Drug Administration (USFDA), which concluded with a single observation. The company said it will address the observation within the stipulated timeline and confirmed that it is not expected to impact ongoing business operations.

Biocon said the Cranbury facility represents a strategic advancement of its operations in the United States, enabling faster access to the company's vertically integrated portfolio of products, benefiting patients in the region. With some p...